Spyre Therapeutics (SYRE) announced that it has commenced an underwritten public offering of $300M of shares of its common stock. Jefferies, Goldman Sachs & Co., Evercore ISI, and Guggenheim Securities are acting as the joint book-running managers for the proposed offering. LifeSci Capital is acting as passive bookrunner for the proposed offering.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics Pauses At-The-Market Equity Offering Program
- Spyre Therapeutics initiated with a Strong Buy at Raymond James
- Buy Rating on SYRE: Early SPY001 Outperformance, Broad IBD Opportunity, and Catalyst‑Rich Path Support Higher $80 Target
- Spyre Therapeutics price target raised to $80 from $65 at Wedbush
- Spyre data ‘exceptional,’ but combos could enable ‘dominance,’ says TD Cowen